Key Statistics for CSL
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (06/2013)
|Est. PEG Ratio
|Market Cap (M AUD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (AUD)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CSL
- Net Income (M/USD)
CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection and pain medicine, skin disorder remedies, antivenoms, anticoagulants and immunoglobulins.
More Company Profile & Key Executives for CSL
|John ShineChairman||Brian A McNameeCEO/Managing Director|
|Paul PerreaultCEO/Managing Director||Gordon NaylorChief Financial Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries